Summary
Antimuscarinic side-effects, which include dry mouth, tachycardia, thickening of mucus possibly sedation, of the antihistamines limited the usefulness of these drugs. The advent of newer agents has reduced the sedative effect of the antihistamine. The data presented here show that one of the newest antihistamines, desloratadine, and a first generation drug, diphenhydramine, are both competitive inhibitors of muscarinic receptor mediated slowing of the heart as measured using a Langendorff preparation. Both agents have apparent sub-micromolar affinities for the muscarinic receptor. Two other agents, cetirizine and fexofenadine, do not interact with muscarinic receptors in the heart at the concentrations used in this study. Structural similarities of the drugs suggest that substitution of a group with a high dipole moment or charge on the side chain nitrogen decreases the binding with muscarinic receptors. We conclude that of the compounds tested fexofenadine and cetirizine have little or no interaction with muscarinic receptors.
Article PDF
Similar content being viewed by others
References
Nicolas J.M. (2000). The metabolic profile of second-generation antihistamines. Allergy 55(Suppl 60): 46–52
Nathan R.A. (2003). Pharmacotherapy for allergic rhinitis: a critical review of leukotriene receptor antagonists compared with other treatments. Ann. Allergy Asthma Immunol. 90: 182–190
Taglialatela M., Pannaccione A., Castaldo P., Giorgio G., Zhou Z., January C.T., Genovese A., Marone G., Annunziato L. (1998). Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. Mol. Pharmacol. 54: 113–121
Taglialatela M., Castald P., Pannaccion A., Giorgi G., Genoves A., Maron G., Annunziat L. (1999). Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity. Clin. Exp. Allergy 29(Suppl 3): 182–189
Kubo N., Shirakawa O., Kuno T., Tanaka C. (1987). Antimuscarinic effects of antihistamines: quantitative evaluation by receptor-binding assay. Jpn. J. Pharmacol. 43: 277–282
Cardelus I., Anton F., Beleta J., Palacios J.M. (1999). Anticholinergic effects of desloratadine, the major metabolite of loratadine, in rabbit and guinea-pig iris smooth muscle. Eur. J. Pharmacol. 374: 249–254
Vergely C., Perrin-Sarrado C., Clermont G., Rochette L. (2002). Postischemic recovery and oxidative stress are independent of nitric-oxide synthases modulation in isolated rat heart. J. Pharmacol. Exp. Ther. 303: 149–157
Arunlakshana O., Schild H.O. (1959). Some quantitative uses of drug antagonists. Br. J. Pharmacol. 14: 48–58
Presa J. (1999). H1 Antihistamines: a review. Alergol. Immunol. Clin. 14: 300–312
Handley D.A., McCullough J.R., Fand Y., Wright S.E., Smith E.R. (1997). Descarboethoxyloratadine, a metabolite of loratadine, is a superior antihistamine. Ann. Allergy Asthma Immunol. 78: P164
Zhang M.Q., Walczynski K., Timmerman H. (1995). A steric approach for the design of antihistamines with low muscarinic receptor antagonism. Inflamm. Res. 44(Suppl 1): S90-S91
Acknowledgement
This work was supported by a grant from Aventis.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liu, H., Zheng, Q. & Farley, J.M. Antimuscarinic actions of antihistamines on the heart. J Biomed Sci 13, 395–401 (2006). https://doi.org/10.1007/s11373-005-9053-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11373-005-9053-7